Therefore, this study aimed to evaluate the efficacy and safety of combining SGLT2 inhibitors with conventional intensive insulin therapy in hospitalised patients with T2DM who presented with severe hyperglycaemia. The gene discussed is SLC5A2; the disease is Hyperglycemia.